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Department, Zeneca Pharmaceuticals, Alderley Park, Macclesfield, UK . 
Objective: To compare the in vitro activity of meropenem with that of other agents with a broad-spectrum of 
antibacterial activity, and which may therefore be candidates for empirical use. The agents tested were imipenem, third- 
generation and newer cephalosporins, penicillins combined with a p-lactamase inhibitor, ciprofloxacin and amino- 
glycosides. 
Methods: Using agar dilution methods, al l  agents were tested against 900 clinical isolates (many of which were 
multiresistant), including Gram-positive aerobes, nutritionally fastidious aerobes, Enterobacteriaceae, non-fermenters 
and anaerobes, collected from 17 UK hospitals during 1994. In addition, some agents were tested against strains 
expressing defined p-lactamases, including extended-spectrum p-lactamases. 
Results: The potency and spectrum of the carbapenems, unequalled against aerobes and anaerobes, were undoubtedly 
influenced by their stability to serine p-lactamases. Meropenem and imipenem exhibited essentially the same spectrum 
of activity but imipenem was often less potent, notably against Gram-negative aerobes, including Pseudomonas 
aeruginosa and Burkholderia cepacia. Conversely, the activity of the third-generation (MICgos 0.016-64 mg/L) and, to 
some extent, the newer cephalosporins (MICgos 0.06-8 mg/L) and the augmented penicillins (MICgos 1 to >I28  mg/L) 
was unreliable against many genera of Enterobacteriaceae because of chromosomally mediated enzymes or the, now 
commonplace, plasmid-mediated p-lactamases. Ciprofloxacin had modest activity (MICgos 1-64 mg/L) against Gram- 
positive aerobes, was potent against nutritionally fastidious species, had again variable activity against the Entero- 
bacteriaceae (MlC90s 0.008-4 mg/L) and was inactive against many strains of Pseudomonas, Burkholderia and 
Acinetobacter, resulting in MICgos of 4 to >I28  mg/L. The aminoglycosides were impressive only against the Entero- 
bacteriaceae, with amikacin alone active (MICgos 2-8 mg/L) against the 11 species tested. 
Conclusions: This study demonstrates that it is difficult on grounds of spectrum to differentiate third-generation 
cephalosporins, and that neither cefepime nor cefpirome materially enhance utility. The study suggests also that, judged 
on activity in vitro, meropenem or imipenem are the only monotherapy options for empirical antibacterial therapy of 
polymicrobic infections or when local epidemiology indicates the predominance of multiresistant Enterobacteriaceae. 
Instability to current and emerging p-lactamases is progressively compromising the use of al l  other p-lactam com- 
pounds. 
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INTRODUCTION 
A major use of broad-spectrum P-lactam antibiotics 
is in the empirical therapy of mono- or polymicrobic 
infections. Inevitably, the extensive use of these agents 
in this setting has resulted in the emergence of chromo- 
somally mediated and plasmid-mediated P-lactamases 
that are progressively compromising the use of most 
P-lactam compounds [l-31. 
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The similarities in structure, general properties, 
spectrum and potency of analogs within a chemical 
class are often poorly understood. Consequently, and 
because of lack of withiii-test data, unnecessary 
confusion can occur when therapeutic options are 
considered. This is particularly the case with cephalo- 
sporins (Figure 1). 
To address this issue, we have compared mero- 
penem with several examples of cephalosporins, 
including the newer agents, cefepime and cefpirome, 
and also the piperacillin/tazobactarn and amoxicillin/ 
clavulanate combinations, against which there are few 
comparisons with meropenem. Ciprofloxacin and 
four aniinoglycosides were included, as were other 
agents, as appropriate for specific organism groups. The 
bacterial strains tested were mostly unselected recent 
clinical isolates collected from 17 laboratories in the 
UK during 1994; many of these clinical strains were 
multiresistant. Additionally, strains known to harbor 
chromosomally mediated or plasmid-mediated p-lacta- 
mases, some of which were extended-spectrum 
p-lactamases (ESBLs) known to hydrolyze popularly 
prescribed cephalosporins, were tested. This permitted 
a comparison of (3-lactamase stability of the carba- 
penems, cephalosporins and penicillins. 
This study differs from others that form an 
extensive body of literature in which the spectrum and 
potency of meropenem has been compared with those 
of a limited number of coniparators. A compilation of 
these studies is presented in this Supplement and 
elsewhere [4-181. The principal objective of this study 
was a comparison of the utility of a wide range of 
(3-lactam antibiotics and hence an assessment of their 
potential in empirical therapy of infections caused by 
single or multiple pathogens. 
MATERIALS AND METHODS 
Antibiotics 
Meropenem was supplied by Zeneca Pharmaceuticals, 
cefepime by Bristol-Myers Squibb Laboratories and 
cefpirome by Hoechst Roussel Pharmaceuticals. All 
other antibiotics, including imipenem, ceftazidime, 
cefotaxime, ceftriaxone, ceftizoxime, amoxicillin, 
amoxicillin/clavulanate, piperacillin, piperacilldtazo- 
bactam, ciprofloxacin, gentamicin, tobramycin, ami- 
kacin and netilmicin were obtained from commercial 
sources. Benzylpenicillin, methicillin, vancomycin, 
teicoplanin, azithromycin, clarithromycin, metroni- 
dazole and clindamycin were tested selectively. 
Bacterial strains 
Nine hundred isolates were tested, including Gram- 
positive aerobes, nutritionally fastihous aerobes, Entero- 
bacteriaceae, non-fernienters and anaerobes. The clinical 
isolates tested were collected from 17 hospitals in 
the UK over a 5-month period during 1994. The 
collection contained many strains resistant to (3-lactam 
antibiotics or aminoglycosides. Each isolate was speci- 
ated fully. Strains known to express characterized 
D-lactamases, either chromosomal or plasmid, were 
included in this study. The plasmid-bearing strains, 
selected on  the basis of being resistant to third- 
generation cephalosporins, were supplied by R. Labia 
and D. Sirot. Refertnce ATCC strains Staphylo- 
coccus anreus 29213, Escherichia rol i  25922, Pseudoinonas 
aeruginosa 27853, Bacteroides fvnxilis 25285, and Clostvi- 
dium pefritzgens 13124 were used for quality control. 
Antimicrobial susceptibility tests 
Minimum inhibitory concentrations (MICs) were 
determined using the agar dilution methods reconi- 
mended by the National Committee for Clinical 
Laboratory Standards (NCCLS) [ 19,201. Aerobes were 
tested on Mueller-Hinton agar, with 5% horse blood 
added for fastidious organisms, and, in a departure from 
NCCLS methods, y-nitrophenyl glycerol (30 mg/L) 
was added to inhibit the spreading of Protens species. 
Wilkins-Chalgren agar plus 5%) horse blood was used 
when testing anaerobic isolates. When weighing 
for use, account was taken of potency, and, when 
appropriate, the presence of cilastatin. An inoculuni 
estimated to be lo4 CFU/spot by comparison with 
a Bas04 opacity standard was used. Plates were 
inoculated with a microtiter multiple inoculator. 
Results were noted following overnight incubation 
(18-24 h) at 37OC in an appropriate environment but 
anaerobes required a longer period of growth, usually 
48 h. Tests that included non-enteric streptococci or 
Haemophilus, Neisseria or Moraxella species were 
incubated in 5% CO:! and anaerobes were incubated in 
an atmosphere of 10% CO2 and 90% N.. The MIC was 
defined as the lowest concentration of antibiotic that 
prevented visible growth: a haze at the point of 
inoculation or one discrete colony was ignored. 
The susceptibilities of the isolates to meropenem and 
the comparators are grouped into broad antibiotic 
classes and presented in Tables 1-4. The focus of 
comments is the relative activity of meropenem and the 
individual comparator agents when judged by MICsos. 
This is done to allow readers to compare meropenem 
with agents in common use in their institutions. 
Comments relating to stability to (j-lactamases are 
based on MIC comparisons against producers or non- 
producers of defined enzymes or general responses to 
4 8 2 2  Clinical Microbiology and Infection, Volume 3 Supplement 4 
Ceftazidime 
coo- 
Cefotaxime 
H2N 
COOH 0 
y 3  
NY0 
Ceftriaxone, 
H2N J+:v&sy!*o disodium salt 
CHj"N' ONa 
COONa 
y 3  
Ceftizoxime 
coo- 
Figure l Chemical structures of the principal cephalosporins. 
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populations of Enterobacteriaceae in which 8-lacta- 
mase-mediated resistance is common. Stenotrophomonas 
maltophilia was not tested, as this species is typically 
insusceptible to rneropenem and all or most of the 
comparators tested. 
Carbapenems (Table 1) 
Iniipenern and meropenem were similar against Gram- 
positive aerobes while meropenem was obviously more 
potent against Enterobacteriaceae, Pseudomonas aerqinosa 
and Burkholderia cepacia. These were the most active 
conipounds tested against methicfin-susceptible staphy- 
lococci and streptococci; imipeneni was 2-4-fold more 
potent than meropenem against Eiztevococcus faecalis and 
Staphylococcus epidermidis. Although the activity of both 
carbapenems was reduced against penicillin-resistant 
Streptococcus pneumonine when compared to susceptible 
strains, the MICW was still only 1 mg/L. All nutri- 
tionally fastidious aerobes tested were hilly susceptible 
to meropeneni, including strains that expressed 
p-lactamase activity. Meropenem was eight-fold more 
potent than imipenem against Haemoplzilus influenzae 
and Neisseria gonorrhoeae (meropenem M I C ~ I J S  of 0.25 
and 0.016 mg/L, respectively). Meropenem was the 
most active compound tested against Moraxella catavrhalis 
and was 4-64-fold more potent than imipeneni against 
Enterobacteriaceae; imipenem MICsos of 4 mg/L 
were recorded against Serratia marcescens, Proteus vulgaris, 
Providencia stuartii and Motganella morganii. Meropenem 
( M I C ~ O  2 mg/L) was two-fold more potent against 
Pseudomonas aeruginosa and eight-fold more active 
against Burkholderia cepacia (MICCIIJ 2 mg/L) than i rn-  
penem. However, the two-fold difference in MICqo for 
Pseudomonas aeruginosa disguised the fact that mero- 
penem 50.5 mg/L inhibited 70 of the 126 strains 
tested, while the same concentration of imipenem 
inhibited one strain only, Gram-negative anaerobes 
tested were slightly more susceptible to meropenem 
than to imipenem, but Clostridiurn d@cile was relatively 
insusceptible to inlipenem (MIC90 16 mg/L). 
Cephalosporins (Table 1) 
Activity against staphylococci was greatest against methi- 
cillin-susceptible Staphylococcus aureus, with cefepime 
(MIC9,I 2 mg/L) being the most active among the 
cephalosporins. 
With the exception of penicdlin-resistant pneumo- 
cocci, each cephalosporin was active against the 
streptococci tested, with ceftazidime and ceftizoxime 
being the least potent agents. The meropenem M I C ~ U  
of 1 mg/L for penicillin-resistant Streptococcus pneu-  
tnoniae was at least two-fold more potent than for the 
cephalosporins that had MIC90s ranging from 2 to 
32 mg/L. Each cephalosporin was inactive (MICW 
> 128 mg/L) against Enterocomis j&calis. Meropenem 
(MICoo 0.25 mg/L) had equivalent activity to ceft- 
azidime against Haemophilus ii$uenzae but was less 
active than cefotaxime, ceftriaxone and ceftizoxime. 
Activity against Moraxella catarrlralis ranged from MIC1,o 
1 to 2 nig/L, compared to the meropeneni value of 
0.13 mg/L. Species of Neissevia tested were exquisitely 
susceptible to the cephalosporins, with MICCII,s of 
50.016 mg/L. While the number of strains of Entero- 
bacteriaceae tested was relatively small (260, repre- 
senting 11 species), it was sufficient to demonstrate 
considerable evidence of cephalosporin resistance or 
diminished susceptibility; this was most common in 
Citvobacter freundi i  and Eizterohacter cloacae, and less 
marked, but still apparent, among Klebsiella pneumonine, 
Serratia marcescens, Provideticia stuavtii and Mopwiella 
motypnii. Cefotaxirne had MICc,l)s of 0.5, 1, 4, 32 and 
128 mg/L for Klebsiella pneumoniae, Motgauella moyani i ,  
Serratia iizarcesceus, Citrobacter freundi i  and Entevobacter 
cloacae, respectively. Ceftazidime, ccftriaxone and cefti- 
zoxinie showed the same trend, with MICt,os of 
232 mg/L always recorded for Citvobacter j e u n d i i  and 
Enterobactcr cloacae. Cefepime and cefpirome were more 
potent than earlier cephalosporins against these two 
species, but MICWS of 1-2 ing/L were seen for 
Citrobacterfveundii and 4-8 mg/L for Enterobacter cloacae. 
As expected, cefotaxime, ceftriaxone and ceftiz- 
oxime showed poor activity against Acinetohacter baumanii 
(MIC9os of 2 3 2  mg/L), poorer activity still against 
Pseudomonas aevuginosa ( M I C ~ O  >128 nig/L) and modest 
activity against Burkholderia cepacia (MICS~JS 8-1 6 nig/L). 
Ceftazidime MICqos were 8 mg/L for each of these 
three species. Cefpirome or cefepime were inferior 
to ceftazidime against A ,  barmanii  and Pseudoinonas 
aeruginosa (MICqo 32 mg/L) but had the same M I C ~ O  
of 8 mg/L against Burkholderia cepacia. While ceftazi- 
dime was the most active cephalosporin tested, it was 
four-fold less potent than meropenem. Each of the 
cephalosporins was inactive against Bactevoider spp. or 
Clostridiurn d f ic i le  (MICqos 2 6 4  mg/L) and had, a t  
best, modest activity against other anaerobes tested. 
Meropenem values ranged from 0.13 to 4 nig/L. 
When activity was assessed against strains known to 
express defined p-lactamases, the older agents failed to 
show any stability (MIC >128 nig/L) to a P99, type I 
cephalosporinase in Enterobactev cloacae. Cefepime and 
cefpirome, with MICs of 1-4 mg/L. were more active 
but obviously not fully stable to this enzyme. The older 
agents varied in their stability to the chromosomal 
K-1 enzyme in Klebsiella oxytoca (MICs 0.13-8 mg/L), 
and neither cefepime nor cefpirome was fully stable, 
with MICs of 2 mg/L. Generally, strains harboring 
TEM-1 or TEM-2, OXA-1 or Om-2, SHV-1 and 
HMS-1 enzymes were susceptible to all agents. 
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However, strains harboring TEM-3 or TEM-5 (ESBLs) 
had MICs of 4-64 mg/L for cefotaxime, ceftazidime, 
ceftriaxone or ceftizoxime. Cefpirome and cefepime 
were more potent but their MICs of 0.25-4 mg/L for 
these strains were significantly poorer than when tested 
against an Escherichia coli expressing the basal level of 
enzyme (MIC 0.008 mg/L). 
Penicillins, with and without a P-lactamase inhibitor 
(Table 1) 
The addition of tazobactam to piperacillin enhanced 
the activity of the parent drug by at least four- 
fold against methicdin-susceptible Staphylococcus aureus 
(MICg,] 4 mg/L), H .  i t g u e n z a e  (MICw 1 mg/L), 
Neisseria gonorrhoeae (MIC9o 1 mg/L), Escherichia coli 
(MICgo 4 mg/L), K. pneumoniae (MIC90 8 mg/L), 
Enterobacter aerogenes (MICco 4 mg/L), Serratia marcescens 
(MIC~U 16 mg/L), Proteus vulgaris (MICgo 1 mg/L) 
and Prouidencia stuartii (8 mg/L), presumably due to 
inhibition of (J-lactamase. However, it was of little or 
no benefit against Citrobacter fveundi i  or Enterobacter 
cloacae, where MICws were 64-128 mg/L. Activity 
against the non-fermenters was 16-128 mg/L. Potency 
was increased against Bacteroides fvagilis and Bacteroides 
species by combining tazobactam with piperacillin, 
giving MIC9o values of 16 mg/L. The data against 
strains harboring known p-lactamases highlighted 
deficits in the role of tazobactam as an inhibitor of these 
enzymes; MICs of 64 mg/L were seen among strains 
harboring both old and recently described plasmid- 
mediated enzymes, and activity against strains harbor- 
ing the P99 or K-1 chromosomal enzymes showed 
little protective effect. The addition of clavulanate to 
amoxicillin essentially achieved the same benefits as 
when tazobactam was added to piperacillin. However, 
many MICs or MICyos remained above 32 mg/L and, 
as expected, no activity was seen against the non- 
fermenters tested. 
The MIC distributions of meropenem, cefpirome, 
cefepime and the piperacillin/tazobactam combination 
for Citrobacter freundi i ,  Enterobacter cloacae and Pseudo- 
monas aeruginosa are presented in Figure 2. Theses 
graphs highlight the presence of a second population 
of strains of Citrobacter freundi i  and Enterobacter cloacae 
resistant or with diminished susceptibility to cefepime, 
cefpirome and piperacillin/tazobactam. Although the 
meropenem for Pseudomonas aerugiuosa was 
2 mg/L, the modal MIC of 0.5 mg/L emphasizes the 
potency advantage of meropenem over newer cephalo- 
sporins and piperacillin/tazobactam. 
Ciprofloxacin (Table 2) 
The ciprofloxacin MIC9" was 1 mg/L for methicillin- 
sensitive Staphylococcus aureus but was 64 mg/L against 
methicillin-resistant strains, while MICoos against 
other staphylococci, streptococci and enterococci were 
2-4 mg/L. Activity against H. i n f u e n z a e  and Neisseria 
species was excellent (MICws 10.016 mg/L) but 
activity against niloraxella catarrhalis was less impressive 
Figure 2 Minimum inhbitory concentration (MIC) 
distributions of meropenem (MEM), cefpirome (CPR), 
cefepime (CPM) and the piperacillidtazobactam (P + T) 
combination for Citrobacterfreundii, Enterobacter cloacae and 
Pseudomonas aeruginosa. 
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(0.25 mg/L). The activity of ciprofloxacin against stuarfii and Serratia ntnrcescens were niodestly suscep- 
Enterobacteriaceae varied from excellent to poor: tible (MICoo 0.5-2 mg/L); and Citvobactev freundii 
Esckerichia coli and Citrobnctev diversus were highly sus- was 'resistant' (MIC,,O 4 in@). Activity against 
ceptihle (MICW 0.016 mg/L); K. pneumoniae, Pvovidencia non-fermenters was, at  best, poor; the MICoos for 
Table 2 Activity of nieropenetri, ciprofloxacin and anlinoglycosides against aerobes 
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'Results shown as individual MIC values. 
AN, amik'icin; UP, ciprofloxacin; GM, gentaniicin; MEM, mcropenem; MS. methicillin-susceptible; MR, methicilli~~-resistant; NET, 
netilmicin; PS, penicillin-susceptible; PR, penicillin-rrsistaiit; TM, tobramycin. 
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Pseudomonas aeruginosa, A. baumanii and Burkholderia 
cepacia were 4, 16 and >128 mg/L, respectively. 
Aminoglycosides (Table 2) 
Among the Gram-positive aerobes tested, only Staphy- 
lococcus aureus was susceptible; netilmicin was the most 
potent and amikacin the least potent (MIC90 0.13 and 
2 mg/L, respectively). The strains of staphylococci 
defined as methicillin resistant were also resistant to 
these aminoglycosides (MICWS 8-1 28 mg/L). Haemo- 
philus, Moraxella and Neisseria species were, at best, only 
moderately susceptible to some agents while frank 
resistance was commonly seen. Among the 11 species 
of Enterobacteriaceae tested, nine were inhibited by 
netilmicin at 5 2  mg/L, while the MIC90 values for 
Serratia marcescens and Providencia stuartii were 4 and 
128 mg/L, respectively. Gentamicin and tobramycin 
were similar in activity profde, with most MICm being 
2-8 mg/L, but with Citrobacter jearndii and Proridencia 
stuartii MICsos were all at 32 mg/L. Amikacin was 
relatively uniform in potency against all species, with 
MIC90s most commonly of 4-8 mg/L and with no 
values >8 mg/L. Activity against non-fermenters was 
always poor or absent but varied somewhat between 
compounds. Each was totally inactive against Burk- 
holderia cepacia (MICso > 128 mg/L). Tobramycin was 
the most potent (MIC90 4 mg/L), and gentamicin the 
least potent (MIC9n > 128 mg/L), against A. baumanii, 
while potency against Pseudomonas aeruginosa was modest 
to poor, with MIC9os of 8-16 mg/L. 
Agents with a limited spectrum of activity 
Benzylpenicillin, methicillin, azithromycin, clarithro- 
mycin, vancomycin and teicoplanin were included in 
tests against staphylococci, streptococci and entero- 
cocci. Results showed that all staphylococci were 
producers of (3-lactamase, that many were resistant 
to the macrolides and that only the glycopeptides were 
active against the methicillin-resistant staphylococci. 
This was as expected from hospital isolates. Many 
penicillin-resistant pneumococci were resistant to the 
macrolides (Table 3). 
The inclusion of metronidazole and clindamycin 
showed that both meropenem and imipenem compared 
favorably with the performance of these anti-anaerobe 
reference agents (Table 4). 
DISCUSSION 
Soon after the introduction of benzylpenicillin, the first 
of the (3-lactam antibiotics, it became apparent that 
bacterial p-lactamases could hydrolyze penicillin to 
produce an antibacterially inactive product. In line 
with this finding, and sometimes almost ahead of 
the introduction of additional p-lactam antibiotics, a 
diversity of (3-lactamases has been either discovered or 
emerged as a consequence of the use of these new 
antibiotics. 
The introduction of cefotaxime and the struc- 
turally similar compounds ceftriaxone and ceftazidime 
or the stabilizing of amoxycillin or piperacdlin by the 
co-administration of an inhibitor of some of the 
p-lactamases appeared to give the antibiotic the upper 
hand, but not for long. The first indication that 
bacterial resistance to these agents or combinations 
would occur came in the acceptance that neither 
clavulanic acid nor tazobactam would fully protect 
amoxicfin or piperacillin, respectively, from hydrolysis 
by chromosomal (3-lactamases commonly expressed by 
members of the Enterobacteriaceae, notably Entero- 
bactrr cloacae, Citrobacter jieundii, Serratia marcescens and 
Pseudomonas aeruginosa. More disturbing is the fact 
Table 3 Activity of carbapenems, penicihns, macrolides and glycopeptides against Gram-positive cocci 
MICru (mg/L) 
Carbapenelnc Penicillins Macrolides Glycopeptides 
Organism (n) MEM IPM PEN DP AZM CLM VA TEI 
Staphylorocl-us aureus (MS) (40) 0.25 0.25 4 4 32 1 1 1 
Staphylococcus aweus (MK) (1 5) 32 64 64 128 > 128 2128 1 1 
Staphylococcus epidermidis (1 5 )  4 1 4 8 >I28 > 128 2 2 
Streptococcus pnrtrrnoniae (PS) (32) 0.008 0.008 0.03 0.25 0.25 0.03 0.5 0.06 
Streptocomu pneumoniae (PR) (26) 1 1 4 32 64 64 1 0.06 
Streptococcus pyoXenes (35) 0.008 0.008 0.016 0.5 2 0.25 0.5 0.06 
Strrptococcur spp. (24) 0.016 0.016 0.03 1 0.03 0.016 1 0.06 
Streptococcus agalactiae (1 4) 0.06 0.06 0.06 2 0.13 0.016 1 0.25 
Eurevororcu.~.~ec~~is (25) 8 4 8 128 > 128 >128 4 0.5 
AZM, azithromycin; CLM, clarithromycin; DP, methicillin; IPM, imipenem; MEM, meropenem; MS, methicillin-susceptible; MR, 
methicillin-resistant; PEN, benzylpenicillin; PS, penicillin-susceptible; PR,  penicillin-resistant; TEI, teicoplanin; VA, vancomycin. 
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Table 4 Activity against anaerobes 
~~ ~ ~~ 
,‘Where PL is 110 ,  M I G , ,  values are presented. 
A +  C. amoxicillin/cl.ivulaIlate; ClP, ciprofloxacin; CM, climdaniycin; IPM, iinipeneni; MEM, meropcnem; MTLI, metronidarolc; 
P + T, piperac.illiii/tazoba~t~iii 
that therapy with these cephalosporins can select a 
population of bacteria that overexpress these enzymes 
and cause failure of therapy. The outgrowth of these 
stably derepressed (AmpC) mutations in Enterobacter, 
Citrobacter, Serratia and Pseudornonas is commonplace 
following therapy with third-generation cephalo- 
sporins, and infection with wild-type examples of these 
bacteria is a contraindication for the use of these agents 
Plasmid-mediated fl-lactamases detected in Entero- 
bacteriaceae before the early 1980s were uniformly 
inhibited by clavulanic acid or tazobactam and did not 
hydrolyze cefotaxime or its close analogs. However, we 
are now confronted with mutations in TEM or SHV 
enzymes that are either resistant to the fl-lactamase 
inhibitors or can hydrolyze the cephalosporins. Ironi- 
cally, these mutant enzymes were first detected when a 
new generation of cephalosporins, to be selected on the 
basis of greater stability to chromosomally mediated 
enzymes, were in the research phase; neither cefepime 
or cefpirome are fully stable to either chromosomal or 
new plasmid enzymes. There are reports that SHV-2, 
SHV-3 and SHV-4, TEM-10 and TEM-12 produce 
marked elevation of the MIC values for cefepime 
and cefpirome, but the activity of meropenem is not 
compromised [23,24]. Currently, among (3-lactam 
antibiotics, only cephamycins and carbapenems are 
unaffected by these TEM- or SHV derivatives but the 
cephamycins are hydrolyzed by the chromosomally 
mediated enzymes [25]. 
Although the spectrum of activity of piper- 
acillin/tazobactam is broader than that of piperacillin 
alone, the addition of tazobactam does not totally 
inhibit the action of chromosomal type I (3-lacta- 
mases when overexpressed. This lack of inhibition has 
been evident in previous studies [26], and strains of 
Gram-negative bacteria producing SEX-3, SHV-4 and 
CARJ-4 ESBLs, and also strains hyperproducing TEM 
and SHV p-lactamases, have been shown to be resistant 
to piperacillin/tazobactam [27]. 
[21,22]. 
Unlike all other classes of fl-lactam antibiotics, 
carbapenems are stable to essentially all bacterial serine 
6-lactamases, whether chroniosomal or plasniid in 
origin including those that hydrolyze cefotaxime, 
ceftriaxone, ceftazidme and cefiizoxime. Carbapenems, 
like other 13-lactams, are susceptible to inactivation by 
a small group of zinc-dependent enzymes (nietallo 
(3-lactamases). These are expressed by Stenotrophornonas 
rnaltophilia, Flavobacteriurn spp. and occasionally Aero- 
rnonas hydrophila or Bncteroides species. However, in- 
fections caused by Stenotvoplzowzonas rnaltophilia are 
localized and not common, no carbapenem therapeutic 
failures due to Flwobacteriuvi spp. or Aevornonas hydro- 
phila have been reported and carbapenem-resistant 
Bacteroides species are uncommon [2X]. 
13-Lactamases are the most significant factor in 
determining resistance to p-lactam antibiotics but 
impaired entry into bacteria and/or altered or novel 
penicillin-binding proteins (PBPs) also play a role 1291. 
The expression of inducible PBPs explains staphylo- 
coccal resistance to all currently available fl-lactanis and 
either diminished susceptibility or frank resistance in 
Streptococcus pneurnoniae [30,3 11. Alarmingly, there has 
been a worldwide increase in the incidence of strains 
of penicillin-resistant Streptococcus pneurnoniae [32], 
many of which have also acquired resistance to other 
antibiotics [33]. The most important consequence 
is treatment failure associated with the use of third- 
generation cephalosporins in meningitis caused by 
penicillin-intermediate or -resistant pneumococci [34]. 
Both inlipenem and meropenem retain activity, albeit 
reduced, against penicillin-resistant pneumococci; mero- 
penem has also been shown to be well tolerated and as 
effective as cephalosporins in the treatment of menin- 
gitis [35,36], but imipenem/cilastatin is contraindicated 
because of seizurogenic potential [37,38]. Thus far, 
there is not a single example of an MIC-related failure 
of meropenem against pneumococci in any body site, 
and only two unsubstantiated claims of an imipenem 
failure outside meningitis. 
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Focusing only on resistance to 13-lactani antibiotics 
does not tell the full story. Resistance to almost all 
classes is seen and often bacteria are resistant to many 
different classes of antibiotic and hence arc inulti- 
resistant. This can be inadvertently disguised by 
conirnonly used expressions; for exxnple, methicillin- 
resistant staphylococci are commonly resistant to 
arninoglycosides and inacrolides, penicillin-resistant 
pneumococci niay also be resistant to macrolides and 
ccphalosporins, while Enterobacteriaceae that are 
(3-lactain resistant are frequently resistant to amino- 
glycosides and/or quinolones. This is exemplified 
in outbreaks caused by rnultiresistant strains of 
K.  yncisrnoriiac that carry plasrnids coding for ESBLs 
and genes coding for ainikacin resistance, allowing 
the transfer of multiple resistance [391. 
The use of an MICW to quantiEy or describe 
susceptibility or resistance of a collection of bacteria to 
antibacterial agents may be simplistic but is now 
coininonplace. In a setting where a prescriber wishes to 
administer an antibiotic empirically, it does offer some 
security that nine out of 10 isolates are likely to be 
susceptible; local epidemiology 1s of considerable 
importance. 
The consequence of all of the above is that the 
infectious disease physician is now regularly confronted 
with patients infected with niultiresistant bacteria and 
with a limited choice of agents to use empirically. Also, 
while it may appear that there is a large nuinber of 
different cephalosporins from which to choose, in t"act 
this is not so. O n  the basis of antibacterial activity in 
vitro, the only point likely to differentiate cefotaxinie, 
ceftriaxone, ceftizoxirne and ceftazidiine is the activity 
of ceftazidinie against wild-type Psiicdonzonas aerq i t iosn;  
however, resistant pseudomonads are so conmion in 
many intensive care units that this differential is of 
little consequence. Neither cefpiroine nor cefepimc 
represent an advance over ceftazidiine as antimicrobial 
therapy against IJsuedomonas awuginosn [40-42]. 
Similarly, there is little to differentiate the various 
aininoglycosides, and this situation will not alter, as 
there are no longer research programs to discover new 
analogs. Conversely, there are nunierous new quino- 
loiics being developed but advances are being sought 
in enhanced potency against Gram-positive aerobes 
and anaerobes without any significant evidence of 
activity against quinolone-resistant Enterobacteriaceae 
or Psuedomonns aerugino.cn. 
Confronted with this situation, there appear to be 
only two options for empirical therapy of severe 
bacterial infections of unknown etiology. These are 
to achieve spectrum expansion by combining several 
agents, perhaps a glycopeptide, an aniinoglycoside/ 
cephalosporin and metronidazole/clindaniycin, or to 
use nionothcrapy with a cai-bapeneni. The former is a 
sound option for Gram-positive aerobes and anaerobes 
(if vanconiycin resistance is absent) but potentially 
unreliable with Enterobac.teriaceae or I'sr~ctlonionas 
nerrqinosa. The use of a c;irlxipeneni may not be as 
successful as a glycopeptide if resistant staphylococci or 
enterococci, notably Enteroroaur jwra l i s ,  are involved, 
but will give security with the vast majority of Grain- 
positive or Gran-negative aerobes or anaerobes. 
The choice of carbapenem in the Western world is 
limited to iniipeiicin or nieropcnem. These agents 
exhibit excellent spectra of rnicrohiological dctivity, 
with few differences between thcin, the m o s t  sign- 
ficant of which may be the greater intrinsic activity of 
nieropeneni against 1'suedornoria.s cierrqiiiosa. Thuf  far, 
seriiie ($-lactanuses that hydrolyze carhapenem\ ;ire 
rare. 
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